Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Prophylaxis Post Coronary Artery Bypass Graft Surgery? by Ramos, Felipson
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
8-15-2009
Is Sotalol A Better Choice Over Metoprolol for
Atrial Fibrillation Prophylaxis Post Coronary
Artery Bypass Graft Surgery?
Felipson Ramos
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Ramos, Felipson, "Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Prophylaxis Post Coronary Artery Bypass Graft
Surgery?" (2009). School of Physician Assistant Studies. Paper 149.
Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation
Prophylaxis Post Coronary Artery Bypass Graft Surgery?
Abstract
Background: Atrial Fibrillation (AF) is the most common arrhythmia post Coronary Artery Bypass Graft
surgery (CABG). Up to 50% of patients who undergo a CABG procedure will have AF. Metoprolol, a
conventional beta-blocker, has been the drug of choice for AF prophylaxis. Sotalol, also a beta-blocker, with
class III antiarrythmic effects, could possibly provide a better prophylaxis intervention of AF post CABG
surgery.
Methods: The focus of this study was to review clinical trials on the comparison between sotalol and
metoprolol. A thorough review of clinical trials within the last twelve years, pertaining to sotalol versus
metoprolol and sotalol versus placebo, were carefully selected and analyzed. Double-blinded and randomized
clinical trials of metoprolol and sotalol were identified by systematic literature search using Medline,
CINAHL, Medscape, and MD consult search engines.
Results: Based on the five clinical trials analyzed, atrial fibrillation incidences were lowest in the sotalol groups
(as low as 12.5 %) versus metoprolol groups (19%), and placebo groups (18%). Data gathered also
demonstrates sotalol and metoprolol reducing hospital length of stay to at least half a day when compared to
placebo.
Conclusion: Metoprolol and Sotalol both reduce the risk of post-operative AF, sotalol having a greater efficacy
than metoprolol in reducing the rates of AF post CABG surgery. It is shown however, that sotalol has added
adverse effects from its class III antiaryhtmic effects in addition to its beta blocking side effects. There is some
evidence, although not significant, that both drugs reduce hospital length of stay (LOS) when compared to
placebo, however, there is no marked difference between the two groups, sotalol and metoprolol.
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Abstract   
 
Background: Atrial Fibrillation (AF) is the most common arrhythmia post Coronary Artery Bypass 
Graft surgery (CABG).  Up to 50% of patients who undergo a CABG procedure will have AF.  
Metoprolol, a conventional beta-blocker, has been the drug of choice for AF prophylaxis.  Sotalol, also 
a beta-blocker, with class III antiarrythmic effects, could possibly provide a better prophylaxis 
intervention of AF post CABG surgery.  
Methods:  The focus of this study was to review clinical trials on the comparison between sotalol and 
metoprolol.  A thorough review of clinical trials within the last twelve years, pertaining to sotalol 
versus metoprolol and sotalol versus placebo, were carefully selected and analyzed.  Double-blinded 
and randomized clinical trials of metoprolol and sotalol were identified by systematic literature search 
using Medline, CINAHL, Medscape, and MD consult search engines. 
Results: Based on the five clinical trials analyzed, atrial fibrillation incidences were lowest in the 
sotalol groups (as low as 12.5 %) versus metoprolol groups (19%), and placebo groups (18%).  Data 
gathered also demonstrates sotalol and metoprolol reducing hospital length of stay to at least half a day 
when compared to placebo. 
Conclusion: Metoprolol and Sotalol both reduce the risk of post-operative AF, sotalol having a greater 
efficacy than metoprolol in reducing the rates of AF post CABG surgery.  It is shown however, that 
sotalol has added adverse effects from its class III antiaryhtmic effects in addition to its beta blocking 
side effects. There is some evidence, although not significant, that both drugs reduce hospital length of 
stay (LOS) when compared to placebo, however, there is no marked difference between the two 
groups, sotalol and metoprolol. 
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Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation 
Prophylaxis Post Coronary Artery Bypass Graft Surgery? 
 
Introduction 
 There are four standard oral drugs administered to patients post CABG surgery.   These oral 
drugs include statins (eg simvastatin), ACE Inhibitors (Lisinopril), Aspirin, and a Beta Blocker 
(Metoprolol), and are usually administered once patients are off the ventilator, weaned off inotrophic 
support, and when they are able to take oral medications without complications.  Low dose metoprolol 
usually begun 12 to 24 hours after surgery is the preferred drug of choice in most physician groups for 
post AF prophylaxis.  Other groups use sotalol to prevent atrial fibrillation post CABG surgery.  Is use 
of metoprolol or sotalol to reduce rates of AF a personal preference or does one have a more 
therapeutic efficacy and safety over the other?  
 AF is a common arrhythmia post Coronary Artery Bypass Graft surgery.  It is more prevalent 
in men and with increasing age.  Age has been identified as one of the most powerful contributing risk 
factors for AF after cardiac surgery.1 Other risk factors include a previous history of AF, mitral 
valvular disease, particularly mitral stenosis, increased left atrial size or cardiomegaly, long bypass and 
aortic cross-clamp times, previous cardiac surgery, chronic obstructive pulmonary disease, and 
obesity.2, 3  
 AF is characterized by disorganized atrial electrical activity and progressive deterioration of 
atrial electrochemical function.  The disturbance of normal atrioventricular synchrony can result in a 
15% to 25% reduction in cardiac output, with the incidence most commonly found in the third or 
fourth day post surgery, and recurrence is common.3 Of the patients destined to experience 
postoperative atrial fibrillation, approximately 90% will do so by the end of the sixth postoperative 
day.2   Post surgical AF is associated with increased mortality and morbidity, due to the high risks of 
thromboembolic events.  The disruption of electromechanical function in AF leads to blood stasis and 
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therefore, promotes the development of thrombus, most commonly in the left atrial appendage.  The 
thrombotic clot may be dislodged and cause a stroke.   
 AF occurs frequently post CABG in 15-40% of patients.2 AF post CABG is probably related to 
the combination of atrial trauma, atrial stretch, atrial ischemia, epicardial inflammation, hypoxia, 
acidosis, electrolyte disturbances, and electrophysiologic changes that accompany sympathetic nervous 
system discharge.8 If prophylactic drug therapy is not initiated, it could lead to devastating 
consequences which include discomfort/anxiety, hemodynamic deterioration, stroke, exposure to the 
risks of antiarythmic treatments, prolongation of hospital stay, increased healthcare costs, and death.2 
 A meta-analysis conducted by Crystal analyzed 52 randomized trials (controlled by placebo or 
routine treatment) of beta-blockers and sotalol in their effectiveness for prevention of post CABG atrial 
fibrillation.1 Twenty seven trials that evaluated beta-blockers for prevention of postoperative AF 
reduced the percentage of patients with AF from 33% in the control group to 19% in the beta-blocker 
group.  There were 8 trials that were reviewed in this meta-analysis that looked at sotalol for 
prevention of postoperative AF.  Sotalol reduced the percentage of patients with AF from 37% in the 
control group to 17% in the sotalol group.  There were 4 trials that were looked at that compared 
sotalol versus conventional beta-blockers.  In the studies examined, sotalol reduced the percentage of 
patients with AF form 22% in the other beta-blocker group to 12% in the sotalol group.  Both 
conventional beta-blockers (-0.66 days) and sotalol (-0.40 days) did not significantly effect hospital 
length of stay.  Based on 12 trials that were reviewed that looked at postoperative stroke, with or 
without treatment, the incidence of stroke was 1.2% in the treatment group and 1.4% in the control 
group. 
 Metoprolol is a Class II beta-blocker.  This drug is commonly used to treat hypertension, chest 
pain or pressure, migraine headaches, performance anxiety, tachycardia, and for cardiac rhythm 
control.  Metoprolol blocks the effect of catcholamines on B1- receptors decreasing AV node 
conduction by prolonging the PR interval.  Since metoprolol is a cardiac B1 receptor blocker, it does 
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not exhibit any membrane stabilizing or intrinsic sympathomimetic activity.  Beta-blockers have been 
extensively studied over the years for postoperative atrial fibrillation.   It is reported that beta-blockers 
should reduce the incidence of AF to 12% to 16% after CABG surgery alone.  Metoprolol will also 
reduce ventricular rate when AF occurs.1 
 Sotalol, in addition to being a beta-blocker, has Vaughan-Williams Class III antiarrhythmic 
effects and appears to be effective in suppressing both supraventricular and ventricular arrhythmias.   
Sotalol is commonly used to treat tachycardia or fast heart beat. Sotalol antagonizes effects of the 
sympathetic nervous system.  It allows prolongation of electrical conduction in the atrial muscle, the 
ventricular muscle, and the atrioventricular accessory pathways in both the antegrade and retrograde 
directions.   Unlike metoprolol, sotalol has both beta1 and beta 2 receptor blocking properties. Previous 
studies show sotalol has effectively prevented postoperative AF compared with placebo.4,5 
  
Materials and Methods 
 A comprehensive literature search was compiled of the most recent studies on atrial fibrillation 
prophylaxis using Ovid, Cinahli, medscape, uptodate, and MD consult. Keywords that were used to 
search for appropriate articles included Sotalol vs Metorpolol, post CABG atrial fibrillation 
prophylaxis, and atrial fibrillation prevention post CABG.  Guidelines from the American College of 
Cardiology, American Heart Association, North American Society of Pacing and Electrophysiology 
were also carefully and thoroughly scanned for relevant articles.  No language restrictions were 
applied.  Earliest data included on this study dated back to 1998 with the most recent clinical trial 
study dating to 2004.  Both double-blinded and non-blinded studies were included.  In addition, all 
studies included had a jaded score of at least 3.  In all the studies that were reviewed the primary 
outcome measure was incidence of postoperative AF.  Results that were excluded were in clinical trials 
that compared other beta-blockers (carvedilol) and amiodarone with sotalol and placebo.  
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Results 
 A total of 5 published articles from 1997 to 2004 on the pharmacological prevention of 
postoperative AF with metoprolol and sotalol were used in this article. (see Table 1) Each article was 
graded using the Jadad scale.  All studies included patients undergoing CABG surgery and had very 
similar on-pump time for the treatment population and placebo (controlled) population for each clinical 
trial.  Most patients were male. All trials used continuous ECG monitoring or holter recordings to 
detect AF patients in the ICU.7,5,4  In the Evrard and Parikka study more than half of the patients were 
on beta-blockers preoperatively.  All 5 studies excluded patients with severely decreased left 
ventricular function.  In addition, patients having had a previous history of CABG surgery or atrial 
fibrillation were excluded.  Five articles were randomized trials and two of those were both 
randomized and double blinded. 
 Evrard took 206 patients and randomized them to a sotaolol group (n=103) and control group 
(n=103) in which patients received beta-blockers or no antiarrhythmic drugs on the first CABG 
postoperative day until discharge.4 There was approximately 16% AF occurrence in the sotalol group 
and 48% in the control group.  There was 1 death in each group, 1 of ischemic event in the sotalol 
group and 1 of pulmonary infection in the control group.  Adverse effects from the sotalol group that 
lead to discontinuation of treatment, were observed in 8 patients and were related to asthma in 3, mild 
heart failure in 2, and reduction in cardiac index in 1.  Torsades de Pointes, a rare but serious adverse 
effect of sotalol, was not observed in either group. 
 Gomes analyzed 85 patients who underwent CABG surgery and were randomized to either 
receive sotalol or placebo before the surgery and who continued to receive the drugs for four days 
postoperatively.5 AF was significantly lower in patients on sotalol (12.5%) as compared with placebo 
(38%).  There was significant bradyarrythmia and hypotension (5%) from drug withdrawal on sotalol 
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and none in placebo.  There was no difference in the sotalol group and placebo group in terms of 
reducing hospital length of stay.  
 The Auer study was a randomized, double blinded trial with a sample size of 253, in which 
patients undergoing CABG received either metoprolol (n=62), amiodarone plus metoprolol (n=63), 
and sotalol (n=63) to assess which drug is superior to placebo (n=65).6 Although amiodarone was 
included in this study, for the purposes of sotalol versus metoprolol, amiodarone results were not 
specifically considered in this review.  In this particular study, patients who were receiving sotalol 
significantly reduced the frequency of AF (20/63 31.7%) compared to patients taking placebo (53.8%).  
Metoprolol alone also reduced rates of AF (25/62 40.3%).   There were more adverse effects of nausea, 
dyspepsia in the sotalol group (28.6%) than metoprolol (19.4%).  There was a higher incidence of 
bradyarrhythmia in the metoprolol group (16.1%), sotalol (12.7%), and placebo (3.1%).  There was no 
significant difference between the length of stay of the placebo group compared to the treatment 
groups.  Patients who had postoperative AF had a significantly longer hospital stay when compared to 
those without AF (14.9 +/- 5.7 vs 10.6 +/= 3.6). 
 The Pfistere ME study, also a double-blinded and randomized clinical trial, looked at a total of 
255 patients who undergone CABG surgery.9   Patients were randomized to a sotalol group (n=126) 
and placebo, controlled group (n=129) prior to surgery.   The low dose sotalol group reduced the rates 
of AF to 26 % compared to the placebo group at 46%.  Also found in the study was the reduction of 
heart rate (74 +/- 12 beats/min) in the sotalol group from (85 +/-15 beats/min) in the placebo group.  
Hospital length of stay was also reduced to almost half a day (10.0 +/- 4.0 days versus 10.4 +/-3.2 
days).  Approximately 5.6% in the sotalol group and 3.9% in the placebo group had side effects to 
treatment.  The most common adverse effect experienced by both groups were bradyarrythmias (3.2% 
in sotalol and 1.6% in placebo).  Other side effects included hypotension, dizziness, nausea, vomiting, 
and headaches, there were, however, no significant difference between the treatment group and control 
group. 
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 The Parikka study was a randomized comparison study of the efficacy between metoprolol and 
sotalol in the prevention of postoperative atrial fibrillation.7 To examine whether sotalol, a beta-blocker 
with class III antiarrythmic effects, is superior to metoprolol, 191 patients undergoing CABG surgery 
were randomized to a sotalol group (n=93) and a metoprolol group (n=98) postoperatively.  AF was 
seen in 32% of the metoprolol group and 16% in the sotalol group.  Ventricular rate did not differ in 
the two study groups; in the sotalol group (127  +/- 32) and the metoprolol patients (129  +/-29).   
  
 
Discussion 
 Although there have been numerous studies on the prevention of post CABG atrial fibrillation, 
the primary goal of this study is to look at the effectiveness of sotalol versus the effectiveness of the 
popular metoprolol in reducing the rates of atrial fibrillation.  Recent studies suggest that prevention of 
AF not only prevents incidences of serious health consequences, but also reduce cost.  Prevention of 
atrial fibrillation is a worthwhile goal. 
 Currently, the standard therapies for atrial fibrillation prevention are beta-blockers, like 
metoprolol, sotalol, and amiodarone, magnesium, and atrial pacing; all which have proven successful 
in reducing AF.  The studies above suggest sotalol to be superior to metprolol by at least 10%.1, 6, 7  
Sotalol however, has a potential to create proarrhythmic effects counterbalancing possible superior 
efficacy.  One of the main reasons to use prophylactic therapy to prevent AF is to reduce hospital 
length of stay, and in turn, cost of care.  Although the difference between metoprolol and sotalol is 
insignificant in reducing hospital length of stay, the Crystal study demonstrates pharmacologic 
treatment to reduce length of stay by at least half a day.1   
 The Evrard study looked at the safety and efficacy of low dose sotalol in not only preventing 
supraventricular arrythmias but also ventricular arrhythmias.4 According to the results of the Evrard 
study, prophylactic use of sotalol reduces the occurrence rates of AF by up to 67%.  It is still unclear if 
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this reduction is from sotalol’s beta blocking effect or in combination with its antiarrythmic effects.  
Some concerns of the study are that only patients whose arrhythmias lasted long enough to be recorded 
were documented.  Short period supraventricular arrhythmias may have been missed.   
 Although the Gomes study demonstrated marked reduction in AF on study patients on low to 
moderate doses of sotalol, there were some limitations in the study. The study reports unclear results 
either coming from sotalol’s beta-blocking activity or from its class III antiarrythmic effects on the 
effects of its reduction of AF.  The authors formulate two explanations for the side effects of sotalol in 
their study: 1) the high adrenergic state, and the use of inotrophs in the postoperative state, may have 
accounted for an absence of significant bradycardia and bradycardia related torsade de pointes type of 
ventricular tachycardia; 2) the dosages of sotalol utilized in this study may have been too low.5    
 The double blinded randomized study conducted by Auer, presented data that showed a trend in 
favor of sotalol over metoprolol in high-risk patients, however, it had some limitations of its own.  It is 
difficult to conclude that sotalol is statistically significantly superior to metoprolol due to the fact the 
population used in this study were AF high risk patients.  Approximately 44.7% of the subjects 
included in the study had concomitant valve surgery in addition to CABG surgery.  The results were 
obtained from a high-risk population with a very high proportion of patients undergoing surgery for 
heart valve disease and should not be directly extrapolated to a population with a different baseline risk 
profile.6 This study includes patients that were taking preoperative B-blockers.  It has been shown that 
use of preoperative beta-blockers could significantly reduce AF postoperatively, although they were 
closely spaced out between sotalol (n=25) and metoprolol (n=24).1 The results may have been skewed 
due to beta-blockers showing marked reduction in post CABG surgery AF, compared to those were not 
receiving treatment preoperatively. 
 Another study demonstrating the superior efficacy of sotalol in reducing AF post CABG 
surgery, when compared to placebo, was the Pfistere ME study.  The study however included patients 
who were on preoperative beta-blockers that had to discontinue their medications prior to surgery. The 
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discontinuation of preoperative beta-blocking medication in some patients may have lead to an 
increased rate of supraventricular arrhythmia.  Again in this study, use of continuous ECG monitoring 
was not accomplished, and thus short episodes of atrial fibrillation may have been missed. 
 The Parrika study, is a unique clinical trial in that it takes sotalol and directly compares its 
efficacy to metoprolol.  The results suggest sotalol’s superiority over metoprolol in the prevention of 
postoperative AF.  The study did not include side effects, if any, experienced by study participants.  
Also excluded from the study, were patients lost to follow up and there was no placebo control group. 
Unlike other studies examined, the Parrika clinical trial examined sotalol’s ability to prolong 
repolarization even with modest doses, suggesting the specific class III effect of sotalol is present. 7 
The study was not designed to compare AF prophylactic therapy with a controlled placebo group and 
thus the success rates of sotalol or metoprolol were not compared to those of a non-treatment group.  
Sotalol demonstrates higher efficacy in prolonging repolarization than with metoprolol, however, 
because of a lack of a control group, it is difficult to quantify actual prolongation percentage to a non-
treatment group.  Another concern arises from the arrhythmia documented only in patients who again 
had arrhythmias that lasted long enough to be recorded.  The shorter arrhythmia periods may have 
been missed. 
 Low to moderate doses of sotalol is an effective prophylactic drug in the prevention of atrial 
fibrillation post CABG surgery.   Sotalol is especially effective in patients who are at high risk of AF.  
What is needed, is a study designed to measure every subject using a holter monitor post CABG to 
prevent missing short AF durations.  Furthermore, since there is an increased risk of bradyarrythmias 
and hypotension with sotalol, a large clinical trial should be conducted to assess at what sotalol dose 
has the largest rates of adverse effects. 
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Conclusion 
 
 The American College of Cardiology (ACC) rates Sotalol, a class B prophylactic drug due to 
its potential side effects and metoprolol a class A.  Based on the literature review sotalol is a very 
reasonable prophylactic drug of choice, especially for patients at high risk (eg. history of AF, heart 
valve surgery) of atrial fibrillation or who have contraindications to beta-blockers.  In addition, the 
results of the literature review support the recommendations by ACC of the use of conventional beta-
blockers (metoprolol) as a standard prophylactic drug of choice for stable and no known history of AF 
in patients undergoing CABG surgery.  Future studies and possible standard guidelines are needed to 
address when to administer sotalol over metoprolol to further reduce the rates of post surgical AF. 
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Table 1 Summary of AF in Sotalol when compared to metoprolol and placebo in five clinical trials. 
 
 
Author Published Study Type Metoprolol AF 
% 
Sotalol AF 
% 
Placebo AF % 
Auer J. 2004 Randomized 40.3% 31.7% 53.8% 
Evrard,P. 2000 Randomized Not tested 16% 48% 
Gomes, J.A. 1999 Randomized, double 
blind 
Not tested 12.5% 18% 
Parikka, H. 1998 Randomized 32% 16% Not tested 
Pfisterer ME 1997 Randomized, double 
blind 
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